Ionis Pharmaceuticals faced a setback when its experimental heart drug pelacarsen failed a Phase 3 trial to reduce cardiovascular events, causing an 8.6% stock drop. However, an analyst from Canaccord Genuity maintained a bullish $85 price target, implying a 46% upside from the current price of $58.09. This suggests confidence in Ionis's other pipeline drugs and long-term strategy despite the clinical failure. The company continues to be a notable player in RNA-targeted therapeutics with strategic partnerships like that with Novartis.
Opus Genetics, a clinical-stage biotech focused on inherited retinal diseases, received a Buy rating and $8 price target from analyst Matthew Caufield in August 2026. The company plans to release topline Phase 1/2 data for its gene therapy OPGx-BEST1...
General Electric (GE) announced it will acquire Consolidated Precision Products (CPP) for $11.75 billion to enhance its aerospace casting production. This strategic move aims to strengthen GE's manufacturing capabilities and accelerate engine technol...
United Natural Foods, Inc. (UNFI) reported a Q4 adjusted EPS of $0.69, surpassing analyst expectations of $0.61, signaling strong profitability. However, revenue slightly missed estimates at $7.64 billion, down 0.7% from the previous year. Despite th...
Casey's General Stores will release its Q3 2026 earnings on September 8 after market close, with analysts expecting an EPS of $6.78 and revenue of $5.56 billion. The company has a strong history of exceeding earnings estimates, with an average surpri...
Verisk Analytics introduced its new Verisk Fraud Discovery platform to enhance fraud prevention for insurers. Barclays adjusted the company's price target to $225, suggesting a 21.1% potential gain from the current stock price of $185.79. The company...
